Heart Center, Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi, 830000, China.
Adv Ther. 2022 Oct;39(10):4523-4532. doi: 10.1007/s12325-022-02227-w. Epub 2022 Jul 7.
There is a paucity of literature on the efficacy and safety of ultrafiltration in Chinese patients with heart failure (HF). Therefore, we aimed to compare the efficacy and safety of ultrafiltration with diuretics and provide information and evidence as to the best approach for patients with HF.
In this single-center, non-randomized interventional study patients with HF either received diuretics or ultrafiltration. The efficacy outcomes included changes in the weight, dyspnea score, and 6-min walk distance from baseline to 48 h after treatment. Safety outcomes were evaluated in both the groups with respect to changes in systolic blood pressure, heart rate, serum creatinine, blood urea nitrogen, blood potassium ion concentration, and blood sodium ion concentration.
A total of 149 patients with HF (diuretics, 73; ultrafiltration, 76) were included. At 48 h, patients in the ultrafiltration group showed significantly greater weight loss and better improvement in dyspnea score and 6-min walk distance compared to patients in the control group (P < 0.05). However, the two groups showed no statistically significant difference in terms of safety outcomes such as systolic blood pressure, heart rate, serum creatinine, blood urea nitrogen, blood potassium ion concentration, and blood sodium ion concentration, suggesting similar safety profiles of both the groups.
Ultrafiltration was associated with greater weight loss and better dyspnea score and 6-min walk distance with similar safety profiles as compared with diuretics. Ultrafiltration can be considered as an optimal option for Chinese patients with HF.
关于心力衰竭（HF）中国患者超滤的疗效和安全性的文献很少。因此，我们旨在比较超滤与利尿剂的疗效和安全性，并为 HF 患者提供最佳治疗方法的信息和证据。
在这项单中心、非随机干预性研究中，HF 患者接受利尿剂或超滤治疗。疗效终点包括治疗后 48 小时内体重、呼吸困难评分和 6 分钟步行距离与基线相比的变化。安全性终点在两组中分别评估收缩压、心率、血清肌酐、血尿素氮、血钾离子浓度和血钠离子浓度的变化。
共纳入 149 例 HF 患者（利尿剂组 73 例，超滤组 76 例）。超滤组患者在 48 小时时体重减轻更明显，呼吸困难评分和 6 分钟步行距离改善更好，与对照组相比差异有统计学意义（P<0.05）。然而，两组在收缩压、心率、血清肌酐、血尿素氮、血钾离子浓度和血钠离子浓度等安全性终点方面无统计学差异，提示两组安全性相似。
与利尿剂相比，超滤可导致更大的体重减轻，呼吸困难评分和 6 分钟步行距离改善更好，且安全性相似。超滤可以被认为是中国 HF 患者的最佳选择。
